


MPS IIID - Sanfilippo syndrome D



Alves, S., Coutinho, MF., Jassal, B., Matos, L.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](https://creativecommons.org/licenses/by/4.0/). For more information see our [license](https://reactome.org/about/reactome-textbook/).

This is just an excerpt of a full-length report for this pathway. To access the complete report, please download it at the [Reactome Textbook](https://reactome.org/about/reactome-textbook/).

14/05/2024

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)

Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)

Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)

Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)


Reactome database release: 88

This document contains 1 pathway and 1 reaction ([see Table of Contents](#))

MPS IIID - Sanfilippo syndrome D ↗

Stable identifier: R-HSA-2206305

Diseases: mucopolysaccharidosis III



Mucopolysaccharidosis III (Sanfilippo syndrome) was described in 1963 by a pediatrician named Sylvester Sanfilippo (J. Pediat. 63: 837-838, 1963, no reference). Mucopolysaccharidosis type IIID (MPS IIID, Sanfilippo syndrome D, MIM:252940) is an autosomal recessive genetic disorder due to the loss of N-acetyl-D-glucosamine 6-sulfatase (GNS; MIM:607664), that hydrolyses the 6-sulfate groups of the N-acetyl-D-glucosamine 6-sulfate units of the glycosaminoglycans (GAGs) heparan sulfate and keratan sulfate. GNS is localized to chromosome 12q14 and has 14 exons spanning 46 kb (Robertson et al. 1988, Mok et al. 2003). Loss of enzyme activity leads to lysosomal accumulation and urinary excretion of heparan sulfate and N-acetylglucosamine 6-sulfate residues (Mok et al. 2003). Keratan sulphate does not accumulate in MPS IIID, as beta-linked N-acetyl-D-glucosamine 6-sulphate can be cleaved by beta-hexosaminidase A (Kresse et al. 1980). This disorder is characterized by progressive mental deterioration but only moderate physical abnormalities and death during the second or third decade of life, presenting a phenotype similar to MPSIIIA (Jones et al. 1997, de Ruijter et al. 2011).

Literature references

Gilberg, W., Fuchs, W., von Figura, K., Paschke, E., Kresse, H. (1980). Sanfilippo disease type D: deficiency of N-acetylglucosamine-6-sulfate sulfatase required for heparan sulfate degradation. *Proc Natl Acad Sci U S A*, 77, 6822-6. ↗

Toone, J., Evans, W., Ianelli, C., Alvord, EC., Sillence, D., Alroy, J. et al. (1997). Human mucopolysaccharidosis IIID: clinical, biochemical, morphological and immunohistochemical characteristics. *J. Neuropathol. Exp. Neurol.*, 56, 1158-67. ↗

Valstar, MJ., Wijburg, FA., de Ruijter, J. (2011). Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies. *Curr Pharm Biotechnol*, 12, 923-30. ↗

Mok, A., Hegele, RA., Cao, H. (2003). Genomic basis of mucopolysaccharidosis type IIID (MIM 252940) revealed by sequencing of GNS encoding N-acetylglucosamine-6-sulfatase. *Genomics*, 81, 1-5. ↗

Callen, DF., Baker, EG., Hopwood, JJ., Morris, CP., Robertson, DA. (1988). Chromosomal localization of the gene for human glucosamine-6-sulphatase to 12q14. *Hum. Genet.*, 79, 175-8. ↗

Editions

2012-04-26	Authored, Edited	Jassal, B.
2012-08-27	Reviewed	Coutinho, MF., Matos, L., Alves, S.

Defective GNS does not hydrolyse 6-sulfate from GlcNAc6S ↗


Location: [MPS IIID - Sanfilippo syndrome D](#)

Stable identifier: R-HSA-2263495

Type: transition

Compartments: lysosomal lumen

Diseases: mucopolysaccharidosis III



Due to the rarity of this disease, only approximately 20 mutations had been described. Recently a study by Valstar et al. revealed 15 of those mutations (Valstar et al. 2010). The group also conducted a literature survey of MPS IIID (MIM:252940). Mutations include R355X (Mok et al. 2003), Q390X (Jansen et al. 2007), Q272X (Beesley et al. 2007) and S94I (Valstar et al. 2010). Other mutations are not detailed here but can be referenced in the Valstar et al. review (Valstar et al. 2010).

Literature references

- Beesley, CE., Concolino, D., Filocamo, M., Winchester, BG., Strisciuglio, P. (2007). Identification and characterisation of an 8.7 kb deletion and a novel nonsense mutation in two Italian families with Sanfilippo syndrome type D (mucopolysaccharidosis IIID). *Mol Genet Metab*, 90, 77-80. ↗
- Kariminejad, R., Willems, PJ., Eckert, D., Czartoryska, B., Omran, H., Tokatli, A. et al. (2010). Mucopolysaccharidosis type IIID: 12 new patients and 15 novel mutations. *Hum Mutat*, 31, E1348-60. ↗
- Andermann, F., Andermann, E., Lissens, W., Silver, K., Kaplan, P., Hegele, RA. et al. (2007). Sanfilippo syndrome type D: natural history and identification of 3 novel mutations in the GNS Gene. *Arch Neurol*, 64, 1629-34. ↗
- Mok, A., Hegele, RA., Cao, H. (2003). Genomic basis of mucopolysaccharidosis type IIID (MIM 252940) revealed by sequencing of GNS encoding N-acetylglucosamine-6-sulfatase. *Genomics*, 81, 1-5. ↗

Editions

2012-05-21	Authored, Edited	Jassal, B.
2012-08-27	Reviewed	Coutinho, MF., Matos, L., Alves, S.

Table of Contents

Introduction	1
❧ MPS IIID - Sanfilippo syndrome D	2
⚙ Defective GNS does not hydrolyse 6-sulfate from GlcNAc6S	3
Table of Contents	4